FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade

FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A inhibitor approved for HS, Cosentyx offers a meaningful new treatm... Biopharmaceuticals, FDA Novartis, Cosentyx, hidradenitis suppurativa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news